Journal of Pharmacy Practice and Community Medicine. 2023, 9(2):7-10 • http://dx.doi.org/10.5530/jppcm.2023.2.3

# Effect of Concurrent Co-Morbidity in the Management of Musculoskeletal Disorders

Saliu Akeem Olanrewaju<sup>1</sup>, Ogwumike O. Omoyemi<sup>2</sup>, Yusuff Tunde Gbonjubola<sup>3,\*</sup>, Alexander E. Gordons<sup>3</sup> <sup>1</sup>State Specialist Hospital, Asubiaro, Osogbo, Osun State, NIGERIA. <sup>2</sup>Department of Physiotherapy, University of Ibadan, Oyo State, NIGERIA. <sup>3</sup>Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Bauchi State, NIGERIA.

> Received: 08-March-2023; Accepted: 16-April-2023.

## \*Correspondence to:

Dr. Yusuff Tunde Gbonjubola, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Bauchi State, NIGERIA. Email: gbonjubola4mercy@gmail.com Copyright: © the author(s),publisher and licensee Indian Academy of Pharmacists. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### Abstract

Musculoskeletal disorders exert a substantial impact on the quality of life of affected individuals as well as placing a major economic burden on work organizations and society in terms of compensation costs in the short term and lost wages in the long-term. Musculoskeletal conditions may occur with or without concurrent chronic conditions, which may affect the effectiveness of physiotherapy management. The impact of co-existing co-morbidities other than the primary diseases the patient is being managed for, on the treatment, and on the outcomes of physiotherapy programs for individual patient cannot be overemphasized. Hence, the purpose of this review was to summarize the management of musculoskeletal disorders and the impact of chronic conditions on their treatment outcome.

Keywords: Musculoskeletal disorder, Comorbidity, Risk factors, Manual therapy, Electrotherapy.

#### INTRODUCTION

Musculoskeletal disorders are made up of diverse illnesses affecting the bones, joints, muscles, and connective tissues are grouped together as musculoskeletal disorders. These conditions may cause discomfort and function loss.<sup>[1]</sup> They are among the most disabling and costly conditions in the United States.<sup>[1]</sup> Musculoskeletal disorders are the second most common cause of disability globally, measured by Years Lived with Disability (YLDs), with low back pain being the most frequent condition.<sup>[2]</sup>

Disorders of the musculoskeletal system are problems that can be brought on by inherited, congenital, or acquired pathologic processes, according to the Social Security Administration (SSA). Traumatic or developmental events, infectious, inflammatory, or degenerative processes, as well as neoplastic, vascular, or toxic/metabolic illnesses, can all cause impairments.<sup>[3]</sup>

Musculoskeletal conditions comprise more than 150 conditions that affect the locomotor system of individuals.<sup>[4]</sup> They vary from abrupt, temporary disorders like fractures, sprains, and strains to chronic conditions linked to continuous functional restrictions and disability. Pain (often persistent) and restrictions in mobility, dexterity, and general level of functioning are the typical symptoms of musculoskeletal problems, which make it harder for people to work.<sup>[4]</sup>

#### Epidemiology

Musculoskeletal conditions are also the biggest contributor to Years Lived with Disability (YLDs) worldwide with approximately 149 million YLDS, accounting for 17% of all YLDs worldwide. According to a recent examination of Global Burden of Disease (GBD) data, 1.71 billion individuals worldwide suffer from musculoskeletal disorders.<sup>[5]</sup> It affected people of all ages worldwide, but the prevalence of musculoskeletal diseases varies by age and diagnosis. By far the most afflicted nations, according to the WHO, are those with high incomes (441 million people), followed by those in the WHO Western Pacific Region (427 million people), and the South-East Asia Region (369 million people). Low back pain accounts for the majority of musculoskeletal problems overall.<sup>[5]</sup> Fractures, which affect 436 million people worldwide, osteoarthritis, which affects 343 million, other injuries, which affect 305 million, neck pain, which affects 222 million, amputations, which affect 175 million, and rheumatoid arthritis are additional contributors to the overall burden of musculoskeletal conditions (14 million).<sup>[5]</sup>

#### **Risk factors for Musculoskeletal Disorders**

Numerous factors, including biomechanical, environmental, psychological, and individual risk factors, might contribute to musculoskeletal disorders.<sup>[6]</sup> The risk factors for musculoskeletal discomfort are present in almost every industry, including business, agriculture, and the healthcare sector.<sup>[7]</sup> A number of factors, in addition to age and sex, have been reported to increase a person's risk of having persistent musculoskeletal pain.<sup>[8]</sup> The common risk factors that cause musculoskeletal disorders may include awkward or static posture.<sup>[9]</sup> Forceful motion,<sup>[10,11]</sup> repetitive motion,<sup>[12]</sup> adverse working environment.<sup>[13,14]</sup>

However, there is mounting evidence that additional factors, such as psychological problems and mental stress, which have been linked to a common risk factor for musculoskeletal pain, particularly among students with relation to their study, are also present. Also, some psychosocial factors (such as job dissatisfaction, limited job control and limited social support from supervisors or colleagues) within the workplace have been associated with musculoskeletal pain.<sup>[15]</sup>

Furthermore, data from community-based studies indicated that specific Personal Attributes (such as height and increased visual demand) are associated with the origin of musculoskeletal pain in some people, however, these may differ from population to population.<sup>[16,17]</sup>

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License



e-ISSN: 2455-3255

#### Types of Musculoskeletal Disorders

Musculoskeletal disorder can be caused by disorders of bones, joints, muscles, tendons, ligaments, bursae, or a combination.<sup>[18]</sup> These can be divided into groups according to the body tissue that is affected, such as bone problems or pain that is typically described as deep, penetrating, or dull. It is most frequently caused by injury, but it can also be brought on by bone infection (osteomyelitis), hormonal issues, tumors,<sup>[19]</sup> muscle disorders which is usually characterized as cramping, pressing quality,<sup>[20]</sup> tendon and ligament pain disorders are often described as "sharp" and is worse when the affected tendon or ligament is stretched or moved and is usually relieved by rest,<sup>[18]</sup> and joint injuries which usually produce a stiff, aching, pain. The discomfort, which can be mild to severe, gets exacerbated as the joint is moved.<sup>[19]</sup>

#### Management of Musculoskeletal Disorders

The use of treatments from one or more clinical disciplines that are included into a comprehensive treatment plan is a multimodal approach to pain management.<sup>[21,22]</sup> Strong evidence supports the idea that taking many drugs at once that have diverse mechanisms of action and target different parts of the body results in superior analgesia and fewer adverse effects. The foundation of multimodal analgesia is this. <sup>[17,23]</sup>

General practitioners, physiotherapists, chiropractors, and osteopaths provide treatment for musculoskeletal diseases using a variety of techniques. These include both pharmacological and non-pharmacological interventions, such as analgesics, Non-Steroidal Anti-Inflammatory Medicines (NSAIDs), and corticosteroid injections. Examples of non-pharmacological treatments include exercise therapy, self-management counseling and education, and manual therapy.<sup>[24]</sup> Pharmacological treatment is often of low value than non-pharmacological intervention when pain is non-specific, chronic or widespread.<sup>[25]</sup>

### Pharmacological Management of Musculoskeletal Disorders Analgesics

Musculoskeletal pain is treated using the three-step WHO analgesic ladder (non-opioids, weak opioids, and strong opioids).<sup>[26]</sup> Paracetamol and cyclooxygenase inhibitors, such as aspirin and non-steroidal anti-inflammatory medications, are a part of the initial stage (NSAIDs). Due to safety concerns, paracetamol is frequently recommended as the medicine of choice.<sup>[27]</sup> When non-opioids have insufficient effect or are poorly tolerated, the next step to consider involves weak opioids, such as tramadol, codeine and dextropropoxyphene. Tramadol is proposed to be the better choice due to its pharmacological profile and effect on pain in several musculoskeletal disorders.<sup>[26,28]</sup> When other methods for treating musculoskeletal pain have failed, strong opioids may be explored if they are a part of an ongoing therapy strategy.<sup>[29]</sup> They should be used with great care and are seldom beneficial in the long-term treatment of musculoskeletal pain.<sup>[25]</sup> Generally, analgesics are beneficial when there is a specific nociceptive component, but often have limited benefit in non-specific or persistent broad pain.<sup>[26,30]</sup>

#### Antidepressants

Tricyclic Antidepressants (TCA), especially amitryptiline, have been found to be useful in the treatment of neuropathic pain<sup>[31]</sup> and also useful for patients with chronic musculoskeletal pain problems, such as fibromyalgia and low back pain.<sup>[32]</sup>

#### Anticonvulsants

Anticonvulsants such as karbamazepin, phenytoin, gabapentin and pregabalin also have a long therapeutic tradition in the treatment of specific neuropathic conditions.<sup>[33,34]</sup> Such particular conditions (such as trigeminal neuralgia, diabetic neuropathy, and post-herpetic neuropathy) may play a significant role in a chronic pain issue that is believed to originate from the musculoskeletal system.<sup>[32]</sup>

#### Non-Pharmacological Management of Musculoskeletal Pain

Physical therapy and patient education using a cognitive approach are the cornerstones of non-pharmacological treatment, and they are best administered together as part of a multi-professional rehabilitation program.<sup>[35]</sup>

#### Therapeutic exercise

Physical therapy manages musculoskeletal pain in large part through exercise. Exercise can take many forms, including walking, running, aerobic activity, weight training, isometric exercises, mobility drills, and activities that encourage the activation and reeducation of particular muscle groups.<sup>[25,36]</sup> Exercise can be very helpful in preventing and treating pain of musculoskeletal causes.<sup>[36]</sup> In all exercise interventions, there is a need for strategies to ensure adherence and compliance with the exercise regimen.<sup>[25]</sup>

#### **Physical modalities**

These modalities could be helpful and effective in treating both acute and persistent pain. Pain is typically induced by muscle spasm, which is reduced by applying heat or cold. Direct muscular damage or underlying primary neurologic or skeletal disease may also be the cause of spasmodic muscle shortening.

Passive treatment programs such as hot packs, massage, and ultrasound may be appropriate for a short period; however, a home exercise program, stretching, and self-applied modalities should be implemented early.<sup>[37]</sup> There are no large landmark clinical trials of these modalities, so evidence must be considered as limited.

#### Cryotherapy

Direct application of therapeutic cold to an injured location reduces bleeding and vasodilation, as well as the local inflammatory reaction, edema generation, and pain perception. For both acute sports-related injuries and long-term painful conditions, the PRICE (protection, rest, ice, compression, and elevation) technique is frequently advised. In patients with peripheral vascular disorders, such as Raynaud's disease, cryotherapy is not advised. The ulnar and peroneal nerves in the medial elbow and head of the fibula, for example, should not be exposed to an extreme low temperature for an extended period.<sup>[37]</sup>

#### Heat therapy

Heat therapy has been proven to be useful in treating subacute and chronic pain disorders by increasing collagen extensibility, blood flow, metabolic rate, and inflammation resolution. Other advantages of heat therapy include reduced pain, muscular spasms, and joint stiffness. Heat increases the pain threshold and reduces spindle excitability by directly affecting it. In order to

#### Olanrewaju, et al.: Musculoskeletal Disorders and Co-Morbidities

relieve musculoskeletal contractures, joint stiffness, and chronic inflammatory illnesses, therapeutic heat application is used in conjunction with extended stretching. This results in decreased discomfort and increased range of motion and function.<sup>[38]</sup>

Superficial heat therapy is contraindicated in cases with sensory impairment, vascular insufficiency, malignancy and infection, while deep heat is contraindicated in pregnancy, sensory deficit, and metal implants.<sup>[39]</sup>

#### Electrotherapy

Electrotherapy modalities (also known as electrophysical agents) are methods of physical therapy that aim to reduce pain and improve function via an increase in energy (electrical, sound, thermal or light) into the body.<sup>[40]</sup> Examples include therapeutic ultrasound, Transcutaneous Electrical Nerve Stimulation (TENS) and interferential therapy. TENS is one of the most commonly used and has been in use since the 1960s.<sup>[41]</sup> The gate control theory of pain, developed by Melzack and Wall, is the foundation for TENS, according to which the preferential activation of big A-fibers prevents the passage of painful impulses.<sup>[37]</sup> It has been utilized to treat both acute and persistent pain, including postoperative pain, complicated regional pain syndrome, phantom limb pain, and peripheral nerve discomfort.

It is contraindicated in patients with a cardiac pacemaker injury.<sup>[42]</sup> TENS has been used anecdotally for low back pain, but studies show conflicting recommendations on the matter. TENS has been shown to be effective in osteoarthritic and neuropathic pain.<sup>[43]</sup>

#### Manual therapy

Manual therapy, including mobilisation, manipulation and massage, can be beneficial in reducing pain and improving function.<sup>[44]</sup> Massage has been found to be effective in the management of chronic low back pain, but spinal manipulations have shown only small benefits.<sup>[44,45]</sup>

# Impact of chronic conditions on the management of musculoskeletal disorders

Almost all countries today attribute chronic diseases and non-communicable diseases as the leading cause of adult mortality, and in the coming ten years, that number is expected to rise by 17%.<sup>[46]</sup> Globally, approximately one in three of all adults suffer from multiple chronic conditions.<sup>[47]</sup>

A chronic condition is a human health condition or disease that is persistent or otherwise long-lasting in its effects or a disease that comes with time.<sup>[48]</sup> They could last for three months or more and cannot be prevented by vaccines or cured by medication nor will they disappear.<sup>[49]</sup> Chronic diseases according to Wilper *et al.* (2008)<sup>[50]</sup> include cancer, Chronic Obstructive Pulmonary Disease (COPD), diabetes mellitus, hypercholesterolemia, asthma, and cardiovascular disease. Chronic Musculoskeletal Conditions (CMCs), which can be brought on by the actual labor or by the workplace environment, gradually worsen over time and have an adverse effect on an individual's functional capacity and quality of life.<sup>[51,52]</sup>

The effect of coexisting comorbidities, distinct from the underlying disease for which patients are being treated (the "index disease"), on the management and results of physiotherapy programs for specific patients, has come to be more widely acknowledged in recent years. However, the treatment of patients with comorbidities in daily practice is still unclear and dependent on the therapist's training and expertise.<sup>[53]</sup>

Comorbidity (such as diabetes mellitus), which adversely impacts the treatment outcomes of the index disease (such as COPD or rheumatoid arthritis), or treatment for one condition, may necessitate adjustments in intervention tactics (e.g., cardiopulmonary endurance training).<sup>[53]</sup>

Physical and occupational therapists must identify comorbidities in order to apply suitable methods aimed at reducing the effects of the comorbidity and establish a reasonable prognosis for their patients.<sup>[54]</sup>

Furthermore, comorbidity may negatively interact with the treatment or natural course of a coexisting disease (e.g., severe osteoarthritis of the knee).<sup>[53]</sup> Therefore, understanding the factors to take into account while using physical therapy on comorbid patients as well as ideas to improve and hasten clinical reasoning may be helpful for healthcare providers in achieving the best possible results.<sup>[53]</sup>

#### CONCLUSION

The hallmark of musculoskeletal disorder is a pain, discomfort and often disability. Some of these conditions may occur simultaneously with background of co-morbid conditions such as hypertension and diabetes etc., and physiotherapy has long been central to the clinical management of people with musculoskeletal disorders. Although, some authors find that physiotherapy management should consider the co-morbid conditions the patient being managed as it may affect the mode of intervention used and in the long run may have an effect on the level of the recovery of the patient.

#### **CONFLICT OF INTEREST**

The authors declare no conflict of interest.

#### REFERENCES

- USBJI (United States Bone and Joint Initiative. The burden of musculoskeletal diseases in the United States (BMus). 3<sup>rd</sup> ed. IL: Rosemont: United States Bone and Joint Initiative; 2014a.
- Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol. December 2010;24(6):769-81. doi: 10.1016/j. berh.2010.10.002, PMID 21665125.
- SSA (Social Security Administration). The blue book. Washington, DC: Social Security Administration; 2008. Listing of impairments—Adult listings (part A).
- World Health Organization. Musculoskeletal conditions 2018 [cited Apr 30, 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/ musculoskeletal-conditions.
- Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. December 19 2021;396(10267):2006-17. doi: 10.1016/S0140-6736(20)32340-0, PMID 33275908.
- Kaufman-Cohen Y, Ratzon NZ. Correlation between risk factors and musculoskeletal disorders among classical musicians. Occup Med (Lond). 2011;61(2):90-5. doi: 10.1093/occmed/kqq196, PMID 21273187.
- Health and Safety Executive. Musculoskeletal Disorders (MSDs); 2004 [cited Nov 12, 2019]. Available from: https://www.hse.gov.uk/msd/msds.htm.
- LeResche L, Mancl LA, Drangsholt MT, Huang G, Von Korff M. Predictors of onset of facial pain and temporomandibular disorders in early adolescence. Pain. 2007;129(3):269-78. doi: 10.1016/j.pain.2006.10.012, PMID 17134830.
- Silverstein B, Clark R. Interventions to reduce work-related musculoskeletal disorders. J Electromyogr Kinesiol. 2004;14(1):135-52. doi: 10.1016/j. jelekin.2003.09.023, PMID 14759759.
- Khan SA, Chew KY. Effect of working characteristics and taught ergonomics on the prevalence of musculoskeletal disorders amongst dental students. BMC Musculoskelet Disord. 2013;14:118. doi: 10.1186/1471-2474-14-118, PMID 23547959.
- Luttmann A, Jäger M, Griefahn B, Caffier G, Liebers F, Steinberg U. Preventing musculoskeletal disorders in the workplace. Geneva: WHO; 2003.

#### Olanrewaju, et al.: Musculoskeletal Disorders and Co-Morbidities

- 12. Canadian Centre for Occupational Health and Safety. Work-related Musculoskeletal Disorders (WMSDs); 2019 [cited Nov 12, 2019]. Available from: https://www.ccohs.ca/oshanswers/diseases/rmirsis.html.
- Asmui M, Hussin A, Paino H. The importance of work environment facilities. Int J Learn Dev. 2012;2(1):289-98. doi: 10.5296/ijld.v2i1.1325.
- Haroon H, Mehmood S, Imtiaz F, Ali SA, Sarfraz M. Musculoskeletal pain and its associated risk factors among medical students of a public sector university in Karachi, Pakistan. J Pak Med Assoc. 2018;68(4):682-88. PMID 29808072.
- Morse T, Bruneau H, Michalak-Turcotte C, Sanders M, Warren N, Dussetschleger J, et al. Musculoskeletal disorders of the neck and shoulder in dental hygienists and dental hygiene students. J Dent Hyg. 2007;81(1):10. PMID 17362608.
- Sadeghi N, Habibi E, Sajjadi S. The relationships between musculoskeletal disorders and anthropometric indices in public vehicle drivers International journal of Collaborative Research on Internal Medicine and Public Health 2012;4.6:1173-84.
- Cho K, Cho HY, Han GS. Risk factors associated with musculoskeletal symptoms in Korean dental practitioners. J Phys Ther Sci. 2016;28(1):56-62. doi: 10.1589/ jpts.28.56, PMID 26957728.
- Villa-Forte A. Introduction to the biology of the musculoskeletal system. MSD manual; 2017 [cited Nov 15, 2019]. Available from: https://www.msdmanuals.com/ home/bonejoint-and-muscle-disorders/biology-of-the-musculoskeletal-system/ introduction-to-the-biology-of-the-musculoskeletal-system.
- Kramer JF, Potter P, Harburn KL, Speechley M, Rollman GB. An upper body musculoskeletal assessment instrument for patients with work-related musculoskeletal disorders: a pilot study. J Hand Ther. 2001;14(2):115-21. doi: 10.1016/s0894-1130(01)80041-7, PMID 11382251.
- Mense S. Muscle pain: mechanisms and Clinical Significance. Dtsch ÄrzteblInt. 2008;105(12):214-9. doi: 10.3238/artzebl.2008.0214, PMID 19629211.
- Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581-624. doi: 10.1037/0033-2909.133.4.581, PMID 17592957.
- Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69(2):119-30. doi: 10.1037/a0035514, PMID 24547798.
- Rawal N. Current issues in postoperative pain management. Eur J Anaesthesiol. 2016;33(3):160-71. doi: 10.1097/EJA.00000000000366, PMID 26509324.
- Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: Asystematic overview of current evidence. PLOS ONE. 2017;12(6):e0178621. doi: 10.1371/ journal.pone.0178621, PMID 28640822.
- Bergman S. Management of musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21(1):153-66. doi: 10.1016/j.berh.2006.10.001, PMID 17350550.
- Reig E. Tramadol in musculoskeletal pain-a survey. Clin Rheumatol. 2002;21(1):S9-11; discussion S11. doi: 10.1007/s100670200030, PMID 11954901.
- Towheed T, Maxwell L, Judd M, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;1: CD004257.
- Mattia C, Coluzzi F. Tramadol: focus on musculoskeletal and neuropathic pain. Minerva Anestesiol. 2005;71(10):565-84. PMID 16163147.
- Kalso E, Allan L, Dobrogowski J, Johnson M, Krcevski-Skvarc N, Macfarlane GJ, et al. Do strong opioids have a role in the early management of back pain? Recommendations from a European expert panel. Curr Med Res Opin. 2005;21(11):1819-28. doi: 10.1185/030079905X65303, PMID 16307703.
- Curatolo M, Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: current perspectives and future prospects. Clin J Pain. 2001;17(1):25-32. doi: 10.1097/00002508-200103000-00005, PMID 11289086.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005;3:CD005454. doi: 10.1002/14651858.CD005454.pub2.
- Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71(3):483-90. PMID 15712623.
- Vinik Al. Diabetic neuropathies. In: LeRoith D, Vinik Al, editors. Controversies in treating diabetes. Contemporary endocrinology. Humana Press. 2008. doi: 10.1007/978-1-59745-572-5\_8.

- Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD001133. doi: 10.1002/14651858.CD001133.pub3.
- Nielson WR, Weir R. Biopsychosocial approaches to the treatment of chronic pain. Clin J Pain. 2001;17(4):S114-27. doi: 10.1097/00002508-200112001-00020, PMID 11783824.
- Wright A, Shika KA. Nonpharmacology treatments for musculoskeletal pain. Clin J Pain. 2001;17(1):33-46.
- El-Tallawy SN, Nalamasu R, Salem GI, LeQuang JAK, Pergolizzi JV, Christo PJ. Management of musculoskeletal pain: an update with emphasis on chronic musculoskeletal pain. Pain Ther. 2021;10(1):181-209. doi: 10.1007/s40122-021-00235-2, PMID 33575952.
- French SD, Cameron M, Walker BF, *et al.* Superficial heat or cold for low backpain. Cochrane Database Syst Rev. 2006;1:CD004750. doi: 10.1002/14651858.CD004750.
- DeLisa JA. DeLisa's physical medicine and rehabilitation. Principles and practice. 5. Philadelphia: Lippincott Williams and Wilkins. 2010. Treatment of the patient with chronic pain. p. 1273-318.
- Page MJ, Green S, Mrocki MA, Surace SJ, Deitch J, McBain B, et al. Electrotherapy modalities for rotator cuff disease. Cochrane Database Syst Rev. 2016;2016(6):CD012225. doi: 10.1002/14651858.CD012225, PMID 27283591.
- Khadilkar A, Milne S, Brosseau L, Robinson V, Saginur M, Shea B, *et al.* Transcutaneous Electrical Nerve Stimulation (TENS) for chronic low-back pain. Cochrane Database Syst Rev. 2005;10(3):CD003008. doi: 10.1002/14651858. CD003008.pub2, PMID 16034883.
- Hansson P, Lundeberg T. Transcutaneous electrical nerve stimulation and acupuncture. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack's textbook of pain. 5. Philadelphia: Elsevier/Churchill Livingstone; 2006. p. 583-90.
- Vance CGT, Dailey DL, Rakel BA, Sluka KA. Using TENS for pain control: the state of the evidence. Pain Manag. 2014;4(3):197-209. doi: 10.2217/pmt.14.13, PMID 24953072.
- 44. Cherkin DC, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain. Ann Intern Med. 2003;138(11):898-906. doi: 10.7326/0003-4819-138-11-200306030-00011, PMID 12779300.
- Furlan AD, Brosseau L, Imamura M, Irvin E. Massage for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 2002;27(17):1896-910. doi: 10.1097/00007632-200209010-00017, PMID 12221356.
- 46. World Health Organization. Preventing musculoskeletal Disorders in the workplace; 2003. *Protecting Workers' Health Series number 5.*
- Hajat C, Stein E. The global burden of multiple chronic conditions: A narrative review. Prev Med Rep. 2018;12:284-93.
- MedicineNet; 2016. Definition of Chronic Disease. Available from: http://www. medicinenet.com/script/main/art.asp?articlekey=33490.
- CDC. Chronic disease overview; 2016. Available from:https://www.cdc.gov// chronicdisease/overview/index.htm.
- Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, Himmelstein DU. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med. 2008;149(3):170-6. doi: 10.7326/0003-4819-149-3-200808050-00006, PMID 18678844.
- Mody GM, Brooks PM. Improving musculoskeletal health: global issues. Best Pract Resp Clin Rheumatol. 2012;26(2):237-49. doi: 10.1016/j.berh.2012.03.002.
- Woolf AD, Gabriel S. Overcoming challenges in order to improve the management of rheumatic and musculoskeletal diseases across the globe. Clin Rheumatol. 2015;34(5):815-7. doi: 10.1007/s10067-015-2862-9, PMID 25700667.
- El Aroussy N, El Aroussy Y. Comorbidity and physical therapy. Comorbidities in Rheumatic diseases. 2017.
- Yeh HJ, Chou YJ, Yang NP, Cheng CC, Huang N. Association between physical therapy and risk of coronary artery disease and dyslipidemia among osteoarthritis patients: a nationwide database study. Arch Phys Med Rehabil. 2016;97(1):8-16. doi: 10.1016/j.apmr.2015.08.410, PMID 26301384.